-
Jacobio Pharmaceuticals Doses First Patient in JAB-21822 Phase IIa Trial for KRAS G12C NSCLC
•
China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) announced the first patient dosed in a Phase IIa trial of its KRAS G12C inhibitor, JAB-21822, for first-line non-small cell lung cancer (NSCLC) with KRAS G12C and STK11 co-mutations. The study follows a Phase I trial that showed a 56.3% objective response…
-
Novartis Partners with Beijing’s Changping District to Expand Drug Development
•
Swiss pharma giant Novartis (NYSE: NVS) has partnered with Beijing’s Changping district government to expand its business footprint in the region, focusing on novel drug development and digital health collaborations. The alliance will drive pilot projects and support local innovation in treatment technologies. Partnership DetailsAnnounced in an online meeting between…
-
GenScript Biotech’s H1 2022 Revenue Rises 32.7% on Carvykti CAR-T Sales
•
Nanjing-based GenScript Biotech, a biopharma and contract research firm, reported a 32.7% year-on-year (YOY) revenue increase to USD 304.7 million for H1 2022. The growth was driven by sales from its CAR-T cell therapy partnership with Johnson & Johnson’s Janssen, offsetting rising group losses. Revenue Breakdown Carvykti MilestonesCarvykti received U.S.…
-
Mayo Clinic Launches Mayflower BioVentures to Accelerate Cell and Gene Therapies
•
The Mayo Clinic, a leading US hospital group, has launched Mayflower BioVentures, a cell and gene therapy accelerator, in partnership with Hibiscus BioVentures and Innoforce Pharmaceuticals. The venture aims to translate lab technologies into viable therapies for unmet patient needs, with leadership from Mayo Clinic clinicians and Hibiscus executives. Collaboration…
-
Biointron Raises USD 72M in Series B to Expand CRO Services and Antibody Platform
•
Shanghai-based Biointron, a recombinant protein/antibody reagent contract research organization (CRO), has raised nearly RMB 500 million (USD 72.4 million) in a Series B round led by Cornerstone Capital, LYFE Capital, and Sky World Capital. The funding will enhance its CRO service capacity, smart manufacturing, R&D, and global expansion. Funding DetailsThe…
-
Simcere Pharma’s H1 2022 Revenue Rises 27% on New Drug Sales, R&D Push
•
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) reported RMB 2.7 billion (USD 391 million) in H1 2022 revenue, up 27.3% year-on-year (YOY), driven by commercialization of six novel drugs. R&D spending hit RMB 652 million (USD 94.4 million), while net profits fell 88.8% YOY to RMB 62 million (USD 8.9…
-
Alphamab Oncology Reports H1 2022 Revenue Growth Driven by Envafolimab Commercialization
•
China-based Alphamab Oncology (HKG: 9966) reported RMB 53.57 million (USD 7.7 million) in H1 2022 revenue, primarily from commercialization and licensing of envafolimab, its PD-L1 inhibitor co-developed with Simcere Pharma and 3D Medicines. The firm also posted RMB 38.75 million (USD 5.6 million) in gross profits. Envafolimab CommercializationEnvafolimab, China’s first…
-
Akeso Bio’s AK112 Wins Breakthrough Designation for First-Line NSCLC
•
China’s Akeso Bio has secured a breakthrough therapy designation (BTD) from the Center for Drug Evaluation (CDE) for its bispecific antibody (BsAb) AK112, targeting programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF), in first-line, locally advanced, or metastatic non-small cell lung cancer (NSCLC) with PD-L1 expression (TPS≥1%). The drug…
-
RemeGen’s H1 2022 Revenue Soars 1,094% on Aidixi, Taiai Sales
•
China-based biotech RemeGen (HKG: 9995) reported RMB 349 million (USD 50.5 million) in revenue for H1 2022, a 1,094.8% year-on-year surge, driven by sales of its two marketed products: Aidixi (disitamab vedotin), a HER2-targeted ADC for cancer, and Taiai (telitacicept), a fusion protein for autoimmune diseases. Product Approvals and Trials…
-
Beijing Adjusts UEBMI Account Management, Boosting Outpatient Coverage
•
The Beijing Municipal Medical Insurance Bureau has adjusted the management of Urban Employee Basic Medical Insurance (UEBMI) accounts, effective September 1. Employee contributions to Basic Medical Insurance (BMI) will now be fully allocated to personal accounts, while employer contributions will go to unified accounts. Retirees will receive a fixed allocation…
-
Junshi Biosciences’ H1 2022 Financials Show Tuoyi Sales Growth Despite Revenue Drop
•
Shanghai-based Junshi Biosciences (HKG: 1877) reported a 55.26% year-on-year (YOY) revenue decline to RMB 946.05 million (USD 136.9 million) in H1 2022, with net losses of RMB 912.4 million (USD 132 million). R&D spending rose 12% YOY to RMB 1.06 billion (USD 153.6 million), while cash reserves stood at RMB…
-
Connect Biopharma Completes Phase I Trial of CBP-174 for Itch in Skin Diseases
•
Sino-US biotech Connect Biopharma Holdings Ltd (NASDAQ: CNTB), headquartered in San Diego, California, and Taicang, Suzhou, China, announced the completion of a Phase I study for CBP-174, its small-molecule H3 receptor antagonist. The drug is being developed to treat pruritus (itch) associated with allergic and inflammatory skin diseases, including atopic…
-
RoosterBio Taps MBL Beijing Biotech as Exclusive Distributor in China
•
US-based RoosterBio Inc. has appointed MBL Beijing Biotech, a subsidiary of JSR Life Sciences Company, as its exclusive distributor in China. MBL will handle sales and distribution of RoosterBio’s expansion media, exosome collection media, bioreactor media, and genetic engineering media to local clients. Product PortfolioRoosterBio’s engineered media are used in…
-
Boehringer, Eli Lilly’s Jardiance Wins NMPA Approval for Heart Failure with Preserved Ejection Fraction
•
Boehringer Ingelheim and Eli Lilly (NYSE: LLY) announced that China’s National Medical Products Administration (NMPA) has approved a new indication for Jardiance (empagliflozin), an SGLT2 inhibitor, to treat heart failure in adult patients with preserved ejection fraction (HFpEF). Previously approved in China for type 2 diabetes and heart failure with…
-
E-nitiate Biopharma Raises RMB 100M in Series A to Advance Autoimmune Disease Drugs
•
China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a drug developer focused on autoimmune diseases, has raised RMB 100 million (USD 14.5 million) in a Series A financing round. The round was led by M Momentum Venture and included contributions from Tailong Capital, Hangzhou Linping State-owned Capital Investment, and Hangzhou Jintou Industry…
-
Kangtai Bio Partners with Philippine Firm on Pneumonia Vaccines
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has partnered with an unnamed Philippine enterprise to promote its 13-valent and 23-valent pneumonia vaccines in the Philippines. The collaboration aims to enhance regulatory filing, promotion, distribution, marketing, and sales, increasing accessibility and affordability in the Philippines and other emerging markets. Vaccine…
-
MicroPort Scientific Posts 10% Revenue Growth Despite COVID-19 in 2022 Interim Results
•
China-based MicroPort Scientific Corp. (HKG: 0853) reported unaudited 2022 interim results ending June 30, 2022, with revenues of USD 405 million, up 10.1% year-on-year (YOY) excluding exchange rate impacts. The growth was driven by strong performance in key business segments despite COVID-19-related challenges. Business Segment Highlights Financial PerformanceThe company reported…
-
Merck’s Gardasil 9-Valent HPV Vaccine Approved for Expanded Age Range in China
•
US-based Merck Sharp & Dohme (MSD; NYSE: MRK) announced that China’s National Medical Products Administration (NMPA) has approved an expanded indication for its Gardasil 9-valent human papillomavirus (HPV) vaccine. The vaccine, initially approved for females aged 16–26, can now be administered to females aged 9–45. Vaccine Details Epidemiological Context Vaccination…
-
Onekdrug Raises Series B+ Funding to Boost Pharmaceutical B2B Services
•
Hunan Wholesale Pharmaceutical Technology Co., Ltd, operating as Onekdrug, has raised tens of millions of US dollars in a Series B+ financing round led by C-Bridge Capital, with contributions from existing investors Cenova Capital and Unicorn Capital Partners. The proceeds will enhance the company’s service capabilities, including operations, technology, and…
-
Sinocelltech’s Ripertamab Wins NMPA Approval for DLBCL Treatment
•
China-based Sinocelltech Group Ltd (SHA: 688520) has received New Drug Application (NDA) approval from the National Medical Products Administration (NMPA) for its biosimilar ripertamab (SCT400), a CD20 monoclonal antibody (mAb) targeting newly diagnosed CD20-positive diffuse large B-cell non-Hodgkin lymphoma (DLBCL). Drug ProfileRipertamab is a biosimilar of Roche’s Mabthera (rituximab) and…
